He's been consulting to the ACW since Dec 2020, so he knows the company well, and they know him and his management style. Also he invested at 0.22 in Feb 2021. He helped PB with 4 fund raises and a listing on the NASDAQ before leaving in October 2018. He's currently the Clinical Pharmacology at University of California, San Francisco. Interesting mix of academic (Uni of California) and fund raising skills. Seems as if he fits what ACW currently needs. Question is after wearing comfy slippers at Uni, does he have the drive? TWT.
Ann: Actinogen appoints Dr Steven Gourlay as CEO, page-12
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $70.90M | |||
| Open | High | Low | Value | Volume |
| 2.3¢ | 2.4¢ | 2.3¢ | $44.25K | 1.881M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 2727066 | 2.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.4¢ | 526273 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| ACW (ASX) Chart |